Fate Therapeutics, Inc. (FATE)
1.835
-0.02
(-0.81%)
USD |
NASDAQ |
Nov 06, 16:00
1.83
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Research and Development Expense (Annual) : 94.03M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 94.03M |
| December 31, 2024 | 116.04M |
| December 31, 2023 | 143.41M |
| December 31, 2022 | 306.70M |
| December 31, 2021 | 209.67M |
| December 31, 2020 | 122.54M |
| December 31, 2019 | 85.58M |
| December 31, 2018 | 54.82M |
| Date | Value |
|---|---|
| December 31, 2017 | 33.39M |
| December 31, 2016 | 25.57M |
| December 31, 2015 | 19.17M |
| December 31, 2014 | 15.94M |
| December 31, 2013 | 11.44M |
| December 31, 2012 | 12.00M |
| December 31, 2011 | 9.858M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| AVITA Medical, Inc. | 20.84M |
| Agenus, Inc. | 79.34M |
| Amgen, Inc. | 6.974B |
| Anika Therapeutics, Inc. | 25.77M |
| BioCryst Pharmaceuticals, Inc. | 164.74M |